Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16
The DOI matches its Crossref record; 26 of the 28 references it cites were found in a registry or an index.
Abstract
D-type cyclins, in association with the cyclin-dependent kinases Cdk4 or Cdk6, promote progression through the G1 phase of the cell cycle by phosphorylating the retinoblastoma protein (RB). The activities of Cdk4 and Cdk6 are constrained by inhibitors such as p16, the product of the CDKN2 gene on human chromosome 9p21 (refs 12-14). The frequent deletion or mutation of CDKN2 in tumour cells suggests that p16 acts as a tumour suppressor. We show that wild-type p16 arrests normal diploid cells in late G1, whereas a tumour-associated mutant of p16 does not. Significantly, the ability of p16 to induce cell-cycle arrest is lost in cells lacking functional RB, including primary fibroblasts from Rb-/- mouse embryos. Thus, loss of p16, overexpression of D-cyclins and loss of RB have similar effects on G1 progression, and may represent a common pathway to tumorigenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, cells lacking functional RB were resistant to p16INK4a-mediated cell cycle arrest, implying that the ability of CDK4 (and later, CDK6) to drive G1 phase progression required RB (33-35) and predicting that chemical CDK4/6 inhibitors would show efficacy only if RB were functionally intact.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [33]
Citations
Cites
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
A cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751
G1 phase progression: Cycling on cue
Sherr, C. J. (1994) · Cell · doi:10.1016/0092-8674(94)90540-1 · Cited by 2,674
Cyclins and cancer II: Cyclin D and CDK inhibitors come of age
Hunter, T., & Pines, J. (1994) · Cell · doi:10.1016/0092-8674(94)90543-6 · Cited by 2,091
pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest
Hannon, G. J., & Beach, D. (1994) · Nature · doi:10.1038/371257a0 · Cited by 1,950
Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., & Carson, D. A. (1994) · Nature · doi:10.1038/368753a0 · Cited by 1,742
Cyclin D1 is a nuclear protein required for cell cycle progression in G1
Baldin, V, Lukas, J., Marcote, M. J., Pagano, M., & Draetta, G. (1993) · Genes & Development · doi:10.1101/gad.7.5.812 · Cited by 1,614
Self-citation(1993) · Genes & Development · doi:10.1101/gad.7.3.331 · Cited by 1,264
Distinct Roles for Cyclin-Dependent Kinases in Cell Cycle Control
van den Heuvel, S., & Harlow, E. (1993) · Science · doi:10.1126/science.8266103 · Cited by 1,092
Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts.
Quelle, D. E., Ashmun, R. A., Shurtleff, S. A., Kato, J. Y., Bar-Sagi, D., Roussel, M. F., & Sherr, C. J. (1993) · Genes & Development · doi:10.1101/gad.7.8.1559 · Cited by 1,032
Research works printed but not linked: 8
- Jiang, W. et al. Oncogene 8, 3447–3457 (1993).
- Lukas, J., Pagano, M., Staskova, Z., Draetta, G. & Bartek, J. Oncogene 9, 707–718 (1994).
- Jen, J. et al. Cancer Res. 54, 6353–6358 (1994).
- Li, Y., Nichols, M. A., Shay, J. W. & Xiong, Y. Cancer Res. 54, 6078–6082 (1994).
- Otterson, G. A., Kratzke, R. A., Coxon, A., Kim, Y. W. & Kaye, F. J. Oncogene 9, 3375–3378 (1994).
- Tam, S. W. Shay, J. W. & Pagano, M. Cancer Res. 54, 5816–5820 (1994).
- Ohta, M. et al. Cancer Res. 54, 5269–5272 (1994).
- Lukas, J. et al. Oncogene (in the press).
Cited by
Items 101–200 of 902
McConnell, B. B., Gregory, F. J., Stott, F. J., Hara, E., & Peters, G. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.1981 · Cited by 238
“They therefore serve as specific inhibitors of cyclin D-dependent kinases and have the capacity to induce a G1 cell cycle arrest by preventing the phosphorylation of the retinoblastoma gene product, pRb (18, 28, 32, 40, 47, 51, 61, 63, 69).”
BackgroundSelf-citationEpigenetic reprogramming of host genes in viral and microbial pathogenesis
Paschos, K., & Allday, M. J. (2010) · Trends in Microbiology · doi:10.1016/j.tim.2010.07.003 · Cited by 229
Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death
Sandig, V., Brand, K., Herwig, S., Lukas, J., Bartek, J., & Strauss, M. (1997) · Nature Medicine · doi:10.1038/nm0397-313 · Cited by 234
Self-citationInactivation of p16 in Human Mammary Epithelial Cells by CpG Island Methylation
Foster, S. A., Wong, D. J., Barrett, M. T., & Galloway, D. A. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.4.1793 · Cited by 229
Lee, R. J., Albanese, C., Stenger, R. J., Watanabe, G., Inghirami, G., Haines, G. K., Webster, M., Muller, W. J., Brugge, J. S., Davis, R. J., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.11.7341 · Cited by 226
Solomon, D. A., Wang, Y., Fox, S. R., Lambeck, T. C., Giesting, S., Lan, Z., Senderowicz, A. M., & Knudsen, E. S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303969200 · Cited by 218
Betz, B. L., Strobeck, M. W., Reisman, D. N., Knudsen, E. S., & Weissman, B. E. (2002) · Oncogene · doi:10.1038/sj.onc.1205706 · Cited by 212
“We also observed a shift of RB to its active/hypophosphorylated form and a loss of cyclin A and Cdk2. p16ink4a is known to trigger an accumula- tion of hypophosphorylated RB by inhibiting Cdk4/6 activity (Koh et al., 1995; Lukas et al., 1995; Serrano et al., 1993).”
BackgroundGauthier, M. L., Berman, H. K., Miller, C., Kozakeiwicz, K., Chew, K., Moore, D., Rabban, J., Chen, Y. Y., Kerlikowske, K., & Tlsty, T. D. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.10.017 · Cited by 214
“Through inhibition of cyclin-dependent kinase (cdk4/6), p16 blocks phosphorylation of Rb and, thus, inhibits E2F targets essential for cell-cycle progression (Dyson, 1998; Harbour and Dean, 2000; Lukas et al., 1995; Medema et al., 1995; Narita et al., 2003; Nevins, 1998; Sellers et al., 1995).”
BackgroundDeGregori, J., Leone, G., Ohtani, K., Miron, A., & Nevins, J. R. (1995) · Genes & Development · doi:10.1101/gad.9.23.2873 · Cited by 210
Inhibition of DNA synthesis by RB: effects on G1/S transition and S-phase progression
Knudsen, E. S., Buckmaster, C., Chen, T.-T., Feramisco, J. R., & Wang, J. Y. J. (1998) · Genes & Development · doi:10.1101/gad.12.15.2278 · Cited by 210
“Ectopic expression of p16ink4a blocks cells in G1, and this is critically dependent on RB (Koh et al. 1995; Lukas et al. 1995; Medema et al. 1995).”
BackgroundEzhevsky, S. A., Ho, A., Becker-Hapak, M., Davis, P. K., & Dowdy, S. F. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.14.4773-4784.2001 · Cited by 207
“mouse embryonic fibroblasts (MEFs) fails to undergo a G1 arrest (25, 31 ), suggesting a linear p16-cyclin D-pRB pathway (51, 56).”
BackgroundFranco, J., Witkiewicz, A. K., & Knudsen, E. S. (2014) · Oncotarget · doi:10.18632/oncotarget.2270 · Cited by 207
Alevizopoulos, K. (1997) · The EMBO Journal · doi:10.1093/emboj/16.17.5322 · Cited by 203
“Expression of p16 or neutralization of cyclin Introduction D–CDK4 also fail to induce G1 arrest in cells lacking functional pRb (Lukas et al., 1994, 1995a,b; Koh et al.,The activities of the cyclin-dependent kinases CDK4 and 1995; Medema et al., 1995).”
BackgroundFitzGerald, M. G., Harkin, D. P., Silva-Arrieta, S., MacDonald, D. J., Lucchina, L. C., Unsal, H., O'Neill, E., Koh, J., Finkelstein, D. M., Isselbacher, K. J., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8541 · Cited by 200
Kurata, S., Matsumoto, M., & Nakajima, H. (1996) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(199609)62:3<314::aid-jcb2>3.0.co;2-u · Cited by 28
El-Mofty, S. K., & Lu, D. W. (2003) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200311000-00010 · Cited by 198
Newt Myotubes Reenter the Cell Cycle by Phosphorylation of the Retinoblastoma Protein
Tanaka, E. M., Gann, A. A. F., Gates, P. B., & Brockes, J. P. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.136.1.155 · Cited by 199
“…S phase or colony formation in cells that express Rb, while inhibition of cyclin D1 is effective in blocking S-phase entry only in cells containing Rb, thus establishing a functional link between CDK4 and Rb in cell cycle control (Guan et al., 1994; Medema et al., 1995; Lukas et al., 1994, 1995).”
Sandhu, C., Garbe, J., Bhattacharya, N., Daksis, J., Pan, C.-H., Yaswen, P., Koh, J., Slingerland, J. M., & Stampfer, M. R. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.5.2458 · Cited by 194
Foster, J. S., Henley, D. C., Bukovsky, A., Seth, P., & Wimalasena, J. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.3.794-810.2001 · Cited by 191
A Molecular Genetic Model of Astrocytoma Histopathology
Louis, D. N. (1997) · Brain Pathology · doi:10.1111/j.1750-3639.1997.tb01062.x · Cited by 199
Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy
Knudsen, E. S., Pruitt, S. C., Hershberger, P. A., Witkiewicz, A. K., & Goodrich, D. W. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.03.005 · Cited by 185
“using antibodies or RNAi)[9], expressing the CDK4/6 inhibitor p16INK4a[10], and more recently by using pharmaceutical CDK4/6 inhibitors[11].”
MethodAdams, P. D., Li, X., Sellers, W. R., Baker, K. B., Leng, X., Harper, J. W., Taya, Y., & Kaelin, W. G. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1068 · Cited by 187
Drosophila Cdk4 is required for normal growth and is dispensable for cell cycle progression
Meyer, C. A. (2000) · The EMBO Journal · doi:10.1093/emboj/19.17.4533 · Cited by 186
Lu, S., Liu, M., Epner, D. E., Tsai, M., & Tsai, M. (1999) · Molecular Endocrinology · doi:10.1210/me.13.3.376 · Cited by 185
Steinman, R., Hoffman, B., Liebermann, D. A., & Fisher, P. B. (1995) · Science · doi:10.1126/science.7716532 · Cited by 183
Knudsen, K. E., Cavenee, W. K., & Arden, K. C. (1999) · PubMed · Cited by 191
Genetic and Epigenetic Signatures in Human Hepatocellular Carcinoma:A Systematic Review
Nishida, N., & Goel, A. (2011) · Current Genomics · doi:10.2174/138920211795564359 · Cited by 180
Cutaneous Photobiology. The Melanocyte vs. the Sun: Who Will Win the Final Round?
Kadekaro, A. L., Kavanagh, R. J., Wakamatsu, K., Ito, S., Pipitone, M. A., & Abdel‐Malek, Z. A. (2003) · Pigment Cell Research · doi:10.1034/j.1600-0749.2003.00088.x · Cited by 180
Bian, Y., Osterheld, M., Fontolliet, C., Bosman, F. T., & Benhattar, J. (2002) · Gastroenterology · doi:10.1053/gast.2002.32370 · Cited by 182
Bettendorf, O., Piffkò, J., & Bànkfalvi, A. (2004) · Oral Oncology · doi:10.1016/j.oraloncology.2003.08.010 · Cited by 176
Involvement of Myc Activity in a G1/S-Promoting Mechanism Parallel to the pRb/E2F Pathway
Santoni-Rugiu, E., Falck, J., Mailand, N., Bartek, J., & Lukas, J. (2000) · Molecular and Cellular Biology · doi:10.1128/.20.10.3497-3509.2000 · Cited by 172
Self-citationFåhraeus, R., Paramio, J. M., Ball, K. L., Laín, S., & Lane, D. P. (1996) · Current Biology · doi:10.1016/s0960-9822(02)00425-6 · Cited by 170
Cell cycle regulation by the retinoblastoma family of growth inhibitory proteins
Beijersbergen, R. L., & Bernards, R. (1996) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(96)00002-9 · Cited by 176
Non-canonical functions of the RB protein in cancer
Dick, F. A., Goodrich, D. W., Sage, J., & Dyson, N. J. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0008-5 · Cited by 168
Parry, D., Mahony, D., Wills, K., & Lees, E. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.1775 · Cited by 174
Self-citationLu, S., Tsai, S. Y., & Tsai, M. (1997) · PubMed · Cited by 191
Diehl, J. A., & Sherr, C. J. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.12.7362 · Cited by 173
Chemoresistance in human ovarian cancer: the role of apoptotic regulators
Fraser, M., Leung, B., Jahani-Asl, A., Yan, X., Thompson, W. E., & Tsang, B. K. (2003) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-1-66 · Cited by 170
Kaneko, Y., Yoshida, K., Handa, M., Toyoda, Y., Nishihira, H., Tanaka, Y., Sasaki, Y., Ishida, S., Higashino, F., & Fujinaga, K. (1996) · Genes, Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199602)15:2<115::aid-gcc6>3.0.co;2-6 · Cited by 239
Inoue, K., & Sherr, C. J. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.3.1590 · Cited by 168
Loss of E2F4 Activity Leads to Abnormal Development of Multiple Cellular Lineages
Rempel, R. E., Saenz-Robles, M. T., Storms, R., Morham, S., Ishida, S., Engel, A., Jakoi, L., Melhem, M. F., Pipas, J. M., Smith, C., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00030-7 · Cited by 171
Inhibition of Cyclin-Dependent Kinase 4 (Cdk4) by Fascaplysin, a Marine Natural Product
Soni, R., Muller, L., Furet, P., Schoepfer, J., Stephan, C., Zumstein-Mecker, S., Fretz, H., & Chaudhuri, B. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3349 · Cited by 166
Involvement of E2F transcription factor family in cancer
Tsantoulis, P. K., & Gorgoulis, V. G. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.005 · Cited by 163
p16 INK4A Participates in a G 1 Arrest Checkpoint in Response to DNA Damage
Shapiro, G. I., Edwards, C. D., Ewen, M. E., & Rollins, B. J. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.1.378 · Cited by 165
Takuwa, N., & Takuwa, Y. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.9.5348 · Cited by 166
Ito, Y., Matsuura, N., Sakon, M., Miyoshi, E., Noda, K., Takeda, T., Umeshita, K., Nagano, H., Nakamori, S., Dono, K., et al. (1999) · Hepatology · doi:10.1002/hep.510300114 · Cited by 162
Biochemical and cellular mechanisms of mammalian CDK inhibitors: a few unresolved issues
Pei, X.-H., & Xiong, Y. (2005) · Oncogene · doi:10.1038/sj.onc.1208611 · Cited by 158
“…activity of p16, and other INK4 proteins, is dependent on the function of both Rb and either p107 or p130 (Guan et al., 1994; Koh et al., 1995; Lukas et al., 1995; Medema et al., 1995; Bruce et al., 2000), and that Rb, through a still yet-to-be determined feedback loop, represses p16…”
BackgroundMelanoma genetics: An update with focus on the CDKN2A(p16)/ARF tumor suppressors
Piepkorn, M. (2000) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2000.104687 · Cited by 162
Blalock, W., Weinstein-Oppenheimer, C., Chang, F., Hoyle, P., Wang, X.-Y., Algate, P., Franklin, R., Oberhaus, S., Steelman, L., & McCubrey, J. (1999) · Leukemia · doi:10.1038/sj.leu.2401493 · Cited by 158
Giarrè, M., Caldeira, S., Malanchi, I., Ciccolini, F., Leão, M. J., & Tommasino, M. (2001) · Journal of Virology · doi:10.1128/jvi.75.10.4705-4712.2001 · Cited by 159
“Ectopic expression of p16 leads to accumulation of hypophosphorylated pRb, sequestration of E2F, and consequent G1 arrest (13).”
BackgroundThe P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung
Beasley, M. B., Lantuéjoul, S., Abbondanzo, S. L., Chu, W., Hasleton, P. S., Travis, W. D., & Brambilla, E. (2003) · Human Pathology · doi:10.1053/hupa.2003.8 · Cited by 158
Jarrard, D. F., Sarkar, S., Shi, Y., Yeager, T. R., Magrane, G., Kinoshita, H., Nassif, N., Meisner, L. F., Newton, M. A., Waldman, F. M., et al. (1999) · PubMed · Cited by 187
Unrestricted cell cycling and cancer
Strauss, M., Lukas, J., & Bartek, J. (1995) · Nature Medicine · doi:10.1038/nm1295-1245 · Cited by 158
Self-citationp16INK4a can initiate an autonomous senescence program
Dai, C. Y., & Enders, G. H. (2000) · Oncogene · doi:10.1038/sj.onc.1203438 · Cited by 169
“…has been implicated in suppression of sarcomas (Cohen and Geradts, 1997; Serrano et al., 1996), and U2-OS is the cell line in which p16INK4a function has been most extensively studied (Koh et al., 1995; Lukas et al., 1995, 1999; McConnell et al., 1999; Medema et al., 1995; Mitra et al., 1999).”
BackgroundOvercoming cellular senescence in human cancer pathogenesis
Yeager, T. R., DeVries, S., Jarrard, D. F., Kao, C., Nakada, S. Y., Moon, T. D., Bruskewitz, R., Stadler, W. M., Meisner, L. F., Gilchrist, K. W., et al. (1998) · Genes & Development · doi:10.1101/gad.12.2.163 · Cited by 152
The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer
Peurala, E., Koivunen, P., Haapasaari, K., Bloigu, R., & Jukkola‐Vuorinen, A. (2013) · Breast Cancer Research · doi:10.1186/bcr3376 · Cited by 150
“The product of the CDKN2 gene, p16, acts as a tumor suppressor [15], while inactivation of the gene has been found to be a common event in nearly half of all human cancers studied [16].”
BackgroundModulation of p27Kip1 levels by the cyclin encoded by Kaposi's sarcoma‐associated herpesvirus
Mann, D. J., Child, E. S., Swanton, C., Laman, H., & Jones, N. (1999) · The EMBO Journal · doi:10.1093/emboj/18.3.654 · Cited by 157
“…cyclin–cdk complexes, p16Ink4a inhibiting the cdks associated with the D-type cyclins (that is, cdk4 and cdk6) and p27Kip1 inhibiting both cyclin D- and cyclin E-dependent activities (Serrano et al., 1993; Kato et al., 1994; Polyak et al., 1994; Toyoshima and Hunter, 1994; Lukas et al., 1995).”
BackgroundSelf-citationRequirements for Cell Cycle Arrest by p16INK4a
Bruce, J. L., Hurford, R. K., Classon, M., Koh, J., & Dyson, N. J. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00072-1 · Cited by 157
Opposing roles of pRB and p107 in adipocyte differentiation
Classon, M., Kennedy, B. K., Mulloy, R., & Harlow, E. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.190343597 · Cited by 146
Heterogeneous proliferative potential in regenerative adult newt cardiomyocytes
Bettencourt‐Dias, M., Mittnacht, S., & Brockes, J. P. (2003) · Journal of Cell Science · doi:10.1242/jcs.00698 · Cited by 152
“The regulation of Rb activity, and possibly one other member of the pocket protein family, is absolutely required for p16-mediated cell cycle arrest (Bruce et al., 2000; Lukas et al., 1995; Medema et al., 1995).”
Expression of Chr9p21 genes CDKN2B (p15), CDKN2A (p16, p14) and MTAP in human atherosclerotic plaque
Holdt, L. M., Sass, K., Gäbel, G., Bergert, H., Thiery, J., & Teupser, D. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.06.029 · Cited by 143
Skalska, L., White, R. E., Franz, M., Ruhmann, M., & Allday, M. J. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000951 · Cited by 136
The INK4 Family of CDK Inhibitors
Carnero, A., & Hannon, G. J. (1998) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-71941-7_3 · Cited by 189
CpG island hypermethylation in progression of esophageal and gastric cancer
Sato, F., & Meltzer, S. J. (2005) · Cancer · doi:10.1002/cncr.21657 · Cited by 143
Ink4a/Arf links senescence and aging
Sharpless, N. E. (2004) · Experimental Gerontology · doi:10.1016/j.exger.2004.06.025 · Cited by 142
Italiano, A., Bianchini, L., Gjernes, E., Keslair, F., Ranchere-Vince, D., Dumollard, J.-M., Haudebourg, J., Leroux, A., Mainguené, C., Terrier, P., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3185 · Cited by 143
“P16INK4a overexpression might be a secondary event to RB1 inactivation, because RB1 repressed P16INK4a at the transcriptional level (30, 31).”
Frequent Aberrant Methylation of p16INK4a in Primary Rat Lung Tumors
Swafford, D. S., Middleton, S. K., Palmisano, W. A., Nikula, K. J., Tesfaigzi, J., Baylin, S. B., Herman, J. G., & Belinsky, S. A. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.3.1366 · Cited by 142
Germline Mutations of the CDKN2 Gene in UK Melanoma Families
Harland, M., Meloni, R., Gruis, N., Pinney, E., Brookes, S., Spurr, N. K., Frischauf, A.-M., Bataille, V., Peters, G., Cuzick, J., et al. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.12.2061 · Cited by 142
Self-citationp19 Arf induces p53-dependent apoptosis during Abelson virus-mediated pre-B cell transformation
Radfar, A., Unnikrishnan, I., Lee, H.-W., DePinho, R. A., & Rosenberg, N. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13194 · Cited by 138
The p16INK4A tumor suppressor regulates cellular oxidative stress
Jenkins, N. C., Liu, T., Cassidy, P., Leachman, S. A., Boucher, K. M., Goodson, A. G., Samadashwily, G., & Grossman, D. (2011) · Oncogene · doi:10.1038/onc.2010.419 · Cited by 138
“The p16 tumor suppressor protein normally inhibits the kinase activity of cyclin-dependent kinases (CDK) 4 and 6, thereby inhibiting the hyperphosphorylation of retinoblastoma (Rb)-related pocket proteins required for cell-cycle progression (Lukas et al., 1995).”
BackgroundInfluentialRetinoblastoma: the disease, gene and protein provide critical leads to understand cancer
DiCiommo, D. P., Gallie, B. L., & Bremner, R. (2000) · Seminars in Cancer Biology · doi:10.1006/scbi.2000.0326 · Cited by 163
Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma.
Flores, J. F., Walker, G. J., Glendening, J. M., Haluska, F. G., Castresana, J. S., Rubio, M., Pastorfide, G. C., Boyer, L. A., Kao, W. H., Bulyk, M. L., et al. (1996) · PubMed · Cited by 169
Genetic Alterations in Esophageal Cancer
Kuwano, H., Kato, H., Miyazaki, T., Fukuchi, M., Masuda, N., Nakajima, M., Fukai, Y., Sohda, M., Kimura, H., & Faried, A. (2004) · Surgery Today · doi:10.1007/s00595-004-2885-3 · Cited by 140
Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling
McWilliams, R. R., Wieben, E. D., Rabe, K. G., Pedersen, K. S., Wu, Y., Sicotte, H., & Petersen, G. M. (2011) · European Journal of Human Genetics · doi:10.1038/ejhg.2010.198 · Cited by 135
Deletions of the INK4A Gene in Superficial Bladder Tumors
Orlow, I., LaRue, H., Osman, I., Lacombe, L., Moore, L., Rabbani, F., Meyer, F., Fradet, Y., & Cordon‐Cardo, C. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65105-x · Cited by 147
Human T-cell leukemia virus type 1 Tax releases cell cycle arrest induced by p16INK4a
Low, K. G., Dorner, L. F., Fernando, D. B., Grossman, J., Jeang, K. T., & Comb, M. J. (1997) · Journal of Virology · doi:10.1128/jvi.71.3.1956-1962.1997 · Cited by 132
Zhang, Y., Ahsan, H., Chen, Y., Lunn, R. M., Wang, L., Chen, S., Lee, P., Chen, C., & Santella, R. M. (2002) · Molecular Carcinogenesis · doi:10.1002/mc.10076 · Cited by 133
The Retinoblastoma Gene: A Prototypic and Multifunctional Tumor Suppressor
Zheng, L., & Lee, W. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5129 · Cited by 157
Shapiro, G. I., Koestner, D. A., Matranga, C. B., & Rollins, B. J. (1999) · PubMed · Cited by 150
Interaction of D-Type Cyclins with a Novel myb-Like Transcription Factor, DMP1
Hirai, H., & Sherr, C. J. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.11.6457 · Cited by 130
Franklin, D. S., & Xiong, Y. (1996) · Molecular Biology of the Cell · doi:10.1091/mbc.7.10.1587 · Cited by 128
Witkiewicz, A. K., & Knudsen, E. S. (2014) · Breast Cancer Research · doi:10.1186/bcr3652 · Cited by 125
“is dependent on RB for function in suppressing cell cycle progression and inducing senescence [17-20].”
BackgroundRivadeneira, D. B., Mayhew, C. N., Thangavel, C., Sotillo, E., Reed, C. A., Graña, X., & Knudsen, E. S. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.007 · Cited by 125
Xia, Y.-P., Zhao, Y., Marcus, J., Jimenez, P. A., Ruben, S. M., Moore, P. A., Khan, F., & Mustoe, T. A. (1999) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199908)188:4<431::aid-path362>3.0.co;2-b · Cited by 129
Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer
Belinsky, S. A. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi020 · Cited by 148
Remke, M., Pfister, S., Kox, C., Toedt, G., Becker, N., Benner, A., Werft, W., Breit, S., Liu, S., Engel, F., et al. (2009) · Blood · doi:10.1182/blood-2008-10-186536 · Cited by 124
Oncogenic aberrations of p16INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control.
Lukáš, J., Aagaard, L., Strauss, M., & Bártek, J. (1995) · PubMed · Cited by 144
Self-citationPalafox, M., Monserrat, L., Bellet, M., Villacampa, G. J., González-Pérez, A., Oliveira, M., Brasó‐Maristany, F., Ibrahimi, N., Kannan, S., Mina, L. B., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32828-6 · Cited by 154
Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest.
Srethapakdi, M., Liu, F., Tavorath, R., & Rosen, N. X. (2000) · PubMed · Cited by 136
Benedict, W. F., Lerner, S. P., Zhou, J., Shen, X., Tokunaga, H., & Czerniak, B. A. (1999) · Oncogene · doi:10.1038/sj.onc.1202452 · Cited by 131
“This p16 overexpression is likely caused by the absence of RB to downregulate p16 protein production, although p16 overexpression has no e ect in the absence of RB (Lukas et al., 1995).”
BackgroundSørensen, C. S., Lukas, C., Kramer, E. R., Peters, J.-M., Bartek, J., & Lukas, J. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.11.3692-3703.2001 · Cited by 127
Self-citationNoda, I., Fujieda, S., Seki, M., Tanaka, N., Sunaga, H., Ohtsubo, T., Tsuzuki, H., Fan, G., & Saitô, H. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990118)80:2<279::aid-ijc18>3.0.co;2-n · Cited by 73
Induction of p21 WAF1/CIP1 and Inhibition of Cdk2 Mediated by the Tumor Suppressor p16 INK4a
Mitra, J., Dai, C. Y., Somasundaram, K., El-Deiry, W. S., Satyamoorthy, K., Herlyn, M., & Enders, G. H. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3916 · Cited by 126
Pan-cancer molecular analysis of the RB tumor suppressor pathway
Knudsen, E. S., Nambiar, R., Rosario, S. R., Smiraglia, D. J., Goodrich, D. W., & Witkiewicz, A. K. (2020) · Communications Biology · doi:10.1038/s42003-020-0873-9 · Cited by 138
Viallard, J.-F., Lacombe, F., Belloc, F., Pellegrin, J., & Reiffers, J. J. (2001) · Cancer/Radiothérapie · doi:10.1016/s1278-3218(01)00087-7 · Cited by 155
Identification of Target Genes of the p16INK4A-pRB-E2F Pathway
Vernell, R., Helin, K., & Müller, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304930200 · Cited by 123
Markey, M. P., Angus, S. P., Strobeck, M. W., Williams, S., Gunawardena, R. W., Aronow, B. J., & Knudsen, E. S. (2002) · PubMed · Cited by 140
Rowland, B. D., Denissov, S. G., Douma, S., Stunnenberg, H. G., Bernards, R., & Peeper, D. S. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00085-5 · Cited by 120
“…and still undergo RASV12- or p19ARF-induced arrest, p21CIP1 likely is not a critical p19ARF/p53 target gene in(Bruce et al., 2000; Koh et al., 1995; Lukas et al., 1995; Medema et al., 1995). p19ARF, too, is a tumor suppressor gene that has this setting (Groth et al., 2000; Pantoja and Serrano,…”
BackgroundLiu, L., Qiu, M., Tan, G., Liang, Z., Qin, Y., Chen, L., Chen, H., & Liu, J. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0305-z · Cited by 125
“p16 was identified as an inhibitor of cyclin-dependent kinase 4 and 6 and thereby leads to hypophosphorylation of pRb [49].”
BackgroundDifferential gene expression in leiomyosarcoma
Skubitz, K. M., & Skubitz, A. P. N. (2003) · Cancer · doi:10.1002/cncr.11586 · Cited by 120
Metadata
- Authors
- Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G., & Bartek, J.
- Affiliations
- Danish Cancer Society (DK)
- ORCID
- Mann, David J.
- Venue
- Nature
- Published
- 1995-06
- Volume
- 375
- Issue
- 6531
- Pages
- 503-506
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2010493387
- Cited by
- 899
- References
- 28
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 6 · 2023: 7 · 2022: 16 · 2021: 15 · 2020: 14 · 2019: 15 · 2018: 17 · 2017: 16 · 2016: 15 · 2015: 15 · 2014: 14 · 2013: 22 · 2012: 16
- FWCI
- 32.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Keywords
- p16, retinoblastoma protein, CDKN2, tumour suppressor, cell cycle arrest, G1 phase progression, D-type cyclins, CDK4, CDK6, retinoblastoma, carcinogenesis, chromosome 9p21
- MeSH terms
- Animals, Carrier Proteins, Cell Cycle, Cells, Cultured, Cloning, Molecular, Escherichia coli, Humans, Mice, Inbred BALB C, Microinjections, Mutation, Proto-Oncogene Proteins, Recombinant Proteins, Tumor Cells, Cultured, Oncogene Proteins, Genes, Tumor Suppressor, Retinoblastoma Protein, G1 Phase, Cyclins, Protein Serine-Threonine Kinases, Cyclin-Dependent Kinases, Cyclin D1, Cyclin-Dependent Kinase Inhibitor p16, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.